Display options
Cite
Arolt C, Hoffmann F, Nachtsheim L, et al. Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. Head Neck Pathol. 2021;doi: 10.1007/s12105-021-01370-0.
Arolt, C., Hoffmann, F., Nachtsheim, L., Wolber, P., Guntinas-Lichius, O., Buettner, R., von Eggeling, F., Quaas, A., & Klußmann, J. P. (2021). Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. Head and neck pathology, . https://doi.org/10.1007/s12105-021-01370-0
Arolt, Christoph, et al. "Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort." Head and neck pathology vol. (2021). doi: https://doi.org/10.1007/s12105-021-01370-0
Arolt C, Hoffmann F, Nachtsheim L, Wolber P, Guntinas-Lichius O, Buettner R, von Eggeling F, Quaas A, Klußmann JP. Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort. Head Neck Pathol. 2021 Aug 10; doi: 10.1007/s12105-021-01370-0. Epub 2021 Aug 10. PMID: 34378164.
Copy Download .nbib Format: NLM
Share it on

Head Neck Pathol. 2021 Aug 10; doi: 10.1007/s12105-021-01370-0. Epub 2021 Aug 10.

Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort.

Head and neck pathology

Christoph Arolt, Franziska Hoffmann, Lisa Nachtsheim, Philipp Wolber, Orlando Guntinas-Lichius, Reinhard Buettner, Ferdinand von Eggeling, Alexander Quaas, Jens Peter Klußmann

Affiliations

  1. Medical Faculty, Institute of Pathology, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. [email protected].
  2. Department of Otorhinolaryngology, MALDI Imaging and Innovative Biophotonics, Jena University Hospital, 07747, Jena, Germany.
  3. Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50937, Cologne, Germany.
  4. Department of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, 07747, Jena, Germany.
  5. Medical Faculty, Institute of Pathology, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  6. MALDI Imaging, Core Unit Proteome Analysis, DFG Core Unit Jena Biophotonic and Imaging, Laboratory (JBIL), Jena University Hospital, 07747, Jena, Germany.
  7. Medical Faculty, Centre for Molecular Medicine Cologne (CMMC), University of Cologne, 50937, Cologne, Germany.

PMID: 34378164 DOI: 10.1007/s12105-021-01370-0

Abstract

Procollagen 11A1 (COL11A1) is a central component of the extracellular matrix in many carcinomas, which is considered to be mainly produced by cancer associated fibroblasts (CAFs). As COL11A1 expression correlates with adverse prognosis and is implicated in chemoresistance, it is a promising putative target. For the first time, we used RNA in-situ hybridization to systematically identify the cells that produce COL11A1 in the ten most prevalent carcinoma types, lymphomas (n = 275) and corresponding normal tissue (n = 55; panCancer cohort). Moreover, as most salivary gland carcinomas (SGC) display distinct stromal architectures, we also analysed 110 SGC. The corresponding protein formation of COL11A1 was determined by MALDI-TOF-MS-Imaging. We report that colon, breast and salivary duct carcinomas are highly infiltrated by COL11A1 positive CAFs (CAFs

© 2021. The Author(s).

Keywords: CAFs; COL11A1; Extracellular matrix; RNA-ISH; Salivary gland carcinoma; Tumour microenvironment

References

  1. Priya SK, Nagare RP, Sneha VS, Sidhanth C, Bindhya S, Manasa P, et al. Tumour angiogenesis—origin of blood vessels. Int J Cancer. 2016;139:729–35. - PubMed
  2. Hernández de la Cruz ON, López-González JS, García-Vázquez R, Salinas-Vera YM, Muñiz-Lino MA, Aguilar-Cazares D, et al. Regulation networks driving vasculogenic mimicry in solid tumors. Front Oncol. 2020;9:1419. - PubMed
  3. Samadi AK, Georgakilas AG, Amedei A, Amin A, Bishayee A, Lokeshwar BL, et al. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol. 2015;35(Suppl):S151–84. - PubMed
  4. Gerarduzzi C, Hartmann U, Leask A, Drobetsky E. The matrix revolution: matricellular proteins and restructuring of the cancer microenvironment. Cancer Res. 2020;80:2705. - PubMed
  5. Wu J, Liang C, Chen M, Su W. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Oncotarget. 2016;7:68954–65. - PubMed
  6. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98. - PubMed
  7. Rafaeva M, Erler JT. Framing cancer progression: influence of the organ- and tumour-specific matrisome. FEBS J. 2020;287:1454–77. - PubMed
  8. Abyaneh HS, Regenold M, McKee TD, Allen C, Gauthier MA. Towards extracellular matrix normalization for improved treatment of solid tumors. Theranostics. 2020;10:1960–80. - PubMed
  9. Jia D, Liu Z, Deng N, Tan TZ, Huang RY-J, Taylor-Harding B, et al. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett. 2016;382:203–14. - PubMed
  10. Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, et al. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Modern Pathol. 2019;32:1460–72. - PubMed
  11. Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, et al. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene. 2018;37:4809–20. - PubMed
  12. Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep. 2016;36:877–85. - PubMed
  13. Ewald JA, Downs TM, Cetnar JP, Ricke WA. Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. PLoS ONE. 2013;8:e55414. - PubMed
  14. Boguslawska J, Kedzierska H, Poplawski P, Rybicka B, Tanski Z, Piekielko-Witkowska A. Expression of genes involved in cellular adhesion and extracellular matrix remodeling correlates with poor survival of patients with renal cancer. J Urol. 2016;195:1892–902. - PubMed
  15. Large TYSL, Mantini G, Meijer LL, Pham TV, Funel N, van Grieken NCT, et al. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight. 2020;5:e138290. - PubMed
  16. García-Pravia C, Galván JA, Gutiérrez-Corral N, Solar-García L, García-Pérez E, García-Ocaña M, et al. Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer. PLoS ONE. 2013;8:e78327. - PubMed
  17. Fischer H, Stenling R, Rubio C, Lindblom A. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001;22:875–8. - PubMed
  18. Fischer H, Salahshor S, Stenling R, Björk J, Lindmark G, Iselius L, et al. COL11A1 in FAP polyps and in sporadic colorectal tumors. BMC Cancer. 2001;1:17. - PubMed
  19. Yoshioka H, Iyama K, Inoguchi K, Khaleduzzaman M, Ninomiya Y, Ramirez F. Developmental pattern of expression of the mouse alpha 1 (XI) collagen gene (Col11a1). Dev Dyn. 1995;204:41–7. - PubMed
  20. Vázquez-Villa F, García-Ocaña M, Galván JA, García-Martínez J, García-Pravia C, Menéndez-Rodríguez P, et al. COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression. Tumour Biol. 2015;36:2213–22. - PubMed
  21. Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18:70. - PubMed
  22. Nallanthighal S, Rada M, Heiserman JP, Cha J, Sage J, Zhou B, et al. Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer. Cell Death Dis. 2020;11:1. - PubMed
  23. Wu Y-H, Chang T-H, Huang Y-F, Chen C-C, Chou C-Y. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget. 2015;6:23748–63. - PubMed
  24. Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608. - PubMed
  25. Arolt C, Meyer M, Ruesseler V, Nachtsheim L, Wuerdemann N, Dreyer T, et al. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. Cancer Immunol Immunother. 2020;69:1363–73. - PubMed
  26. Kesar N, Winkelmann R, Oppermann J, Ghanaati S, Martin D, Neumayer T, et al. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Oral Oncol. 2020;111:104931. - PubMed
  27. Xu B, Jungbluth AA, Frosina D, Alzumaili B, Aleynick N, Slodkowska E, et al. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology. 2019;75:672–82. - PubMed
  28. Arolt C, Meyer M, Hoffmann F, Wagener-Ryczek S, Schwarz D, Nachtsheim L, et al. Expression profiling of extracellular matrix genes reveals global and entity-specific characteristics in adenoid cystic, mucoepidermoid and salivary duct carcinomas. Cancers (Basel). 2020;12:2466. - PubMed
  29. Cancer Statistics [Internet]. SEER. [cited 2020 Oct 17]. Available from: https://seer.cancer.gov/statistics/index.html - PubMed
  30. Wang F, Flanagan J, Su N, Wang L-C, Bui S, Nielson A, et al. RNAscope. J Mol Diagn. 2012;14:22–9. - PubMed
  31. Create Elegant Data Visualisations Using the Grammar of Graphics [Internet]. [cited 2020 Oct 18]. Available from: https://ggplot2.tidyverse.org/ - PubMed
  32. Halsted KC, Bowen KB, Bond L, Luman SE, Jorcyk CL, Fyffe WE, et al. Collagen α1(XI) in normal and malignant breast tissue. Modern Pathol. 2008;21:1246–54. - PubMed
  33. Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 2018;8:304–19. - PubMed
  34. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977;37:4669–71. - PubMed
  35. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83. - PubMed
  36. Cheon D-J, Tong Y, Sim M-S, Dering J, Berel D, Cui X, et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014;20:711–23. - PubMed
  37. Zhao Y, Zhou T, Li A, Yao H, He F, Wang L, et al. A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. Anat Rec (Hoboken). 2009;292:692–700. - PubMed
  38. Cox TR, Bird D, Baker A-M, Barker HE, Ho MW-Y, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73:1721–32. - PubMed
  39. Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Al Mazeedi MAM, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci. 2017;18:1586. - PubMed
  40. Kechagia JZ, Ivaska J, Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment. Nat Rev Mol Cell Biol. 2019;20:457–73. - PubMed
  41. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5:1020–7. - PubMed
  42. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Wirapati P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15:68–74. - PubMed
  43. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372:1335–41. - PubMed
  44. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280–8. - PubMed
  45. Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, et al. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Mol Cancer Res. 2020;18:1088–98. - PubMed
  46. Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, et al. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther. 2014;13:2361–71. - PubMed
  47. Wang Y-N, Zeng Z-L, Lu J, Wang Y, Liu Z-X, He M-M, et al. CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene. 2018;37:6025–40. - PubMed
  48. Li Q, Huang P, Zheng C, Wang J, Ge M. Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis. Oncotarget. 2017;8:29458–73. - PubMed
  49. Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11:5077. - PubMed
  50. Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579–96. - PubMed
  51. Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Modern Pathol. 2013;26:1041–50. - PubMed

Publication Types